A disappointing Q2 for Bayer
One of the world's most recognized pharmaceutical companies, the German conglomerate Bayer, posted its quarterly earnings, and the figures came in lower-than-expected.
Bayer posted earnings per share of €2.67, and revenue of €10.05 billion, underperforming analysts' expectations. The consensus forecasted €10.57 billion worth of revenue and an EPS of €1.5.
Its quarterly sales dropped from a previous €13 billion to €11 billion.
Revenues from the Pharmaceutical segment slipped 8.8% to €3.992 million, as some treatments got postponed due to the pandemic. Among the most affected are ophthalmic and radiological products.
Bayer offered further guidance. It expects that the growth in sales will reach a high of €44 billion, from a previous top of €45 billion. Also, the EPS is seen at a high of €6.90, downgraded from a prior high of €7.20.
Since the beginning of the year, Bayer stocks dropped by 21%, while Germany30 lost 4.89%.
CAPEX.com brings you the latest financial news!
Sources: finance.yahoo.com, investing.com
Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.
Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.
